▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #341 by analyst upside · 2026-09-27
NAUT
Nautilus Biotechnology, Inc.
Healthcare · Market Cap $123M · P/E 0x
ANALYST PRICE TARGET
+315.5%
implied upside to consensus target
Current Price $0.96
Consensus Target $4.0
Bull Target $4.0
Bear Target $4.0
Analysts Covering 2
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
0
Sell
0
52-Week Low $0.79
52-Week High $4.31
YTD Return -49.6%
FUNDAMENTALS
Market Cap $123M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.45
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.79
52-Week High $4.31
Current Price $0.96
Bear Target $4.0
Bull Target $4.0
● Now $0.96 ● Target $4.0
TRADING DATA
Avg Volume 941K
YTD Return -49.6%
Analyst Count 2
Consensus Buy
Upside to Target +315.5%
Last Updated 2026-09-27

ANALYST SUMMARY

Nautilus Biotechnology, Inc. (NAUT) is currently trading at $0.96 with a Wall Street consensus price target of $4.0, implying potential upside of 315.5% over the next 12 months. 2 analysts currently cover NAUT, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $4.0, while the most cautious has a target of $4.0.

NAUT operates in the Healthcare sector with a market capitalisation of $123M. The stock is down 49.6% year-to-date and is currently trading near the lower end of its 52-week range of $0.79 – $4.31.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

SPRO +306.5%
Spero Therapeutics, Inc.
$72M · P/E 8.8x · Buy
PLX +304.4%
Protalix BioTherapeutics, Inc.
$219M · P/E 11.8x · Buy
CCLD +257.7%
CareCloud, Inc.
$87M · P/E 29.3x · Strong Buy
QTTB +381.8%
Q32 Bio Inc.
$261M · P/E 2.8x · Buy
XFOR +285.4%
X4 Pharmaceuticals, Inc.
$298M · P/E 2.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for NAUT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners ● Initiated
Outperform 2026-09-09 29% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-02-27 62% win rate (8 calls)
Goldman Sachs ↓ Downgrade
Neutral → Sell 2024-12-05 Building track record
Guggenheim ● Initiated
Buy 2024-06-27 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
8/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →